Abstract Critical illness comprises a heterogeneous group of serious medical conditions that typically involve an initial proinflammatory process. A compensatory anti-inflammatory response may occur that, if severe and persistent, places the patient at high risk for adverse outcomes including secondary infection and death. Monitoring strategies can identify these patients through measurement of innate and adaptive immune function. Reductions in monocyte HLA-DR expression, reduced cytokine production capacity, increased inhibitory cell surface molecule expression, and lymphopenia have all been associated with this immunesuppressed state. Intriguing data suggest that critical illness-induced immune suppression may be reversible with agents such as interferon-γ, granulocyte macrophage colony-stimulating factor, interleukin 7, or anti-programmed death-1 therapy. Future approaches for characterization of patient-specific immune derangements and individualized treatment could revolutionize how we recognize and prevent complications in critically ill patients.
T he immune system plays a major role in the acute phase of critical illness, as well as late manifestations that result in morbidity and mortality. It comprises a complex network of barriers, cells, and mediators that are activated upon injury or cellular stress and functions to detect and destroy pathogens. Once activated, several cellular and molecular events ensue that involve the innate and adaptive immune systems. These systems have separate functions, yet are intricately interconnected. Innate immune cells respond rapidly and serve to identify broad classes of pathogens, ingest and kill them, and digest them into antigenic peptides for display on antigen-presenting molecules. In addition, innate immune cells produce cytokines and chemokines to make the local environment favorable for fighting infection and to recruit other immune cells to the area. These cells include neutrophils, dendritic cells, natural killer (NK) cells, monocytes, and macrophages.
The adaptive immune response is generated by lymphocytes, including T cells, which are responsible for cytokine production and cytotoxic activity, and B cells, which are responsible for antibody production. These cells have highly antigen-specific receptors and typically require presentation of that antigen by a member of the innate immune system in order to become activated. Lymphocytes can persist for life, providing immunologic memory and the capacity for rapid response in the event of reexposure to the same pathogen. The first response of a naïve lymphocyte to a pathogen, however, can take days to manifest fully. Accordingly, the initial immunologic response to critical illness is often mediated by the innate immune system with the adaptive response most likely being more prevalent in the subacute phase of illness.
Many diagnoses that require intensive care unit (ICU) support involve an acute injury that results in
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Critical illness-induced immune suppression is most likely a multifactoral process. The compensatory anti-infl ammatory response syndrome (CARS) has evolved to serve as a counterregulatory mechanism in the face of systemic infl ammation. This syndrome involves the elaboration of anti-infl ammatory mediators such as IL-10, which serves to down-regulate the proinfl ammatory response and inhibit leukocyte function. If the CARS state is severe and persistent, it represents a form of secondary immune defi ciency that can profoundly affect both innate and adaptive immune function ( Figure 1 ).
Critical illness-induced immune suppression has been demonstrated in children and adults with a variety of diagnoses, including trauma, 4 ,5 sepsis, [6] [7] [8] pancreatitis, 9,10 severe viral infections, 11, 12 and following cardiopulmonary bypass. 13, 14 The clinical consequences of immune suppression in the ICU setting include increased risk of multiple organ dysfunction syndrome, 15 increased susceptibility to secondary bacterial infections, 4, 7, 16 reactivation of latent viruses, 17 susceptibility to opportunistic organisms, 18, 19 and increased risk of death. 6, 7, 20 Now that most critically ill patients are surviving the acute phase of their illness as the result of advances in supportive care, many patients are facing the subacute or chronic phases of their illness bearing the additional burden of secondary immune suppression.
What Causes Critical Illness-Induced Immune Suppression?
Critical illness-induced immune suppression is likely a multifactorial process. Overall, 3 broad categories of factors appear to contribute to its incidence and severity: patient-related factors, illness-related factors, and treatment-related factors.
Figure 1
The dynamic immune response to critical illness. Over time, patients with critical illness typically experience surges in both pro-and anti-infl ammatory mediators. Those who recover uneventfully typically experience more modest and short-lived systemic infl ammatory response syndrome (SIRS) and compensatory anti-infl ammatory response syndrome (CARS) responses (light colors), with immunologic homeostasis being quickly restored. Patients who experience more severe and persistent pro-and anti-infl ammatory responses (dark colors) are at higher risk for adverse outcomes including secondary infection and death. The SIRS and CARS responses can be quantifi ed in the laboratory.
Diagnosis of Critical Illness-Induced Immune Suppression
The use of plasma proteins to identify patients with immune suppression has been challenging given that levels of both proinflammatory and anti-inflammatory mediators are commonly elevated at the same time. 1, 11 White blood cell gene expression data in critically ill patients have suggested upregulation of innate immune signaling and suppressed adaptive immune signaling in several studies, 32, 33 although this finding has not been universally observed. 34 Functional immune monitoring offers an opportunity to quantify the degree of immune compromise in ICU patients. Although many of these tests are not currently available in the clinical laboratory in the United States, they have the potential to inform our understanding of the immunobiology of critical illness in the research setting (Table 1) .
Innate Immune Monitoring
Monocytes display antigens on their cell surfaces via human leukocyte antigen (HLA)-DR molecules. HLA-DR expression can be easily measured by flow cytometry. More than 90% of healthy monocytes express HLA-DR, and they do so at a density of more than 8000 molecules per cell. Suppressed monocytes internalize their HLA-DR molecules. If less than 30% of monocytes strongly express HLA-DR, or if the expression level is fewer than 8000 molecules per cell, multiple investigators have demonstrated increased risks for adverse outcomes from critical illness. 7, 20, 35, 36 Healthy innate immune cells should also produce robust amounts of proinflammatory cytokines when stimulated ex vivo with lipopolysaccharide. In the setting of immune suppression, these cells will be unable to respond to this new challenge and will produce low amounts of cytokine. Indeed, reduced whole blood ex vivo lipopolysaccharide-induced tumor necrosis factor (TNF)-α production capacity has been associated with increased risks for secondary infection and death in sepsis, critical viral infections, trauma, and cardiopulmonary bypass. 4, 7, 11, 37, 38 
Adaptive Immune Monitoring
Perhaps the most readily available marker of adaptive immune function in critical illness is the absolute lymphocyte count. Lymphocyte apoptosis, with resultant lymphopenia and cellular dropout in lymphoid organs, has been repeatedly associated 
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Evidence strongly suggests that critical illness-induced immune suppression has the potential to be reversed.
associated with severe immune suppression following cardiopulmonary bypass in children. 22 The degree to which a patient is at risk for critical illness-induced immune suppression may well be influenced by other patient factors including age, sex, and race, although large-scale evaluation of these factors has not yet been undertaken.
Illness-Related Factors
It has been observed across multiple diagnostic categories that the degree of initial inflammation observed with a critical illness or injury often correlates with the severity of subsequent immune suppression. 4, 11, 23 In the case of traumatic injury, the severity of the initial injury is often associated with the development of impaired immune function in the ICU. 5, 24 Moreover, certain types of injury are prone to greater degrees of immune suppression. Brain injury, for example, has long been known to severely impair host defense, most likely through neurohormonal mechanisms. 25, 26 Last, in the case of illnesses related to infection, it appears that some pathogens may promote immune suppression in the host more than others. Secondary infection with Staphylococcus aureus, for example, was associated with dramatically increased risks for immune suppression developing in a cohort of critically ill children with influenza when compared with children co-infected with other organisms. 
Treatment-Related Factors
Many of the therapies employed in the ICU have overt or unintentional immunomodulatory properties. Patients with malignant neoplasms, autoimmune disease, and transplants receive exogenous immune suppressants, including glucocorticoids, calcineurin inhibitors, and antineoplastic agents that promote or worsen critical illnessinduced immune suppression. Indeed, tapering of doses of these medications can be an important strategy when managing these patients in the ICU. 7, 27 It is also important to acknowledge, however, that many medications routinely used in the ICU for other reasons may have immunosuppressive effects. Examples include sedatives, opioids, catecholamines, and some antibiotics. Transfusion of blood products, particularly red blood cells with long storage durations, has also been suggested to be immunosuppressive in the setting of critical illness. 28, 29 Last, for patients requiring surgical intervention, surgery itself has been linked to reduced immune responses in the postoperative period.
with mortality and secondary infection risk in adults and children with sepsis. [39] [40] [41] The function of the remaining T cells is poor in some circumstances, with the degree of T-cell dysfunction predictive of adverse outcomes. [42] [43] [44] Lymphocytes can also express high levels of negative costimulatory cell surface molecules, such as programmed death (PD)-1, in critical illness. 45, 46 These molecules, when ligated, promote apoptosis or cellular deactivation. Patients with sepsis whose cells demonstrate increased cell surface inhibitory molecule expression are at increased risk for secondary infections and mortality, providing evidence for another distinguishing marker of immune suppression. 47, 48 Last, regulatory T cells are a highly immunosuppressive subset of T cells that are known to produce large quantities of anti-inflammatory cytokines. They appear to be resistant to apoptosis and can predominate in the subacute phase of sepsis in adults 49 although this has not been seen in children.
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Treatment of Critical Illness-Induced Immune Suppression
Recent evidence strongly suggests that critical illness-induced immune suppression has the potential to be reversed through agents known to stimulate either innate or adaptive immune function. Table 2 provides a summary of the evidence available from human trials.
Innate Immune-Stimulating Agents
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). GM-CSF is a cytokine that accelerates the production of neutrophils and monocytes from the bone marrow and enhances the activity of these cells in circulation and in tissues. GM-CSF is approved by the Food and Drug Administration for bone marrow reconstitution following chemotherapy and bone marrow transplant and has been used off-label for immunomodulation in critically ill adults and children. 7, [58] [59] [60] [61] [62] Taken as a whole, these studies suggest that GM-CSF can promote restoration of monocyte HLA-DR expression, improve neutrophil function, and increase TNF-α production capacity. Potential clinical benefits include resolution of infection, prevention of nosocomial infection, and shorter durations of mechanical ventilation, ICU stays, and hospital stays, although these outcomes have yet to be evaluated in large trials. Of note, no serious adverse events were ascribed to GM-CSF in any of these studies, nor did GM-CSF therapy result in increased systemic inflammation as measured by plasma IL-6 levels. Table 1 Common laboratory abnormalities associated with immune suppression in critically ill patients Interferon Gamma (IFN-γ) . IFN-γ is a cytokine that plays a major role in activating lymphocytes, NK cells, monocytes, and macrophages. It has therefore been identified as a candidate drug to stimulate innate and adaptive immune function in critical illness. Use of IFN-γ has been associated with improvements in both monocyte HLA-DR expression and cytokine production capacity and was associated with lower incidence of ventilator-associated infection after severe trauma and improved clearance of invasive infections in fungal sepsis in several small studies. 35, [50] [51] [52] [53] [54] In 1 large randomized controlled trial (RCT) of 416 injured adults, IFN-γ or placebo was given for 21 days or until hospital discharge, with those in the IFN-γ group demonstrating a Table 2 Selected human studies evaluating drugs targeting innate and adaptive immune suppression in critical illness Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-γ, interferon gamma; IL, interleukin; mHLA-DR: monocyte HLA-DR expression, MODS, multiple organ dysfunction syndrome; PD, programed death; RCT, randomized controlled trial; TNF, tumor necrosis factor.
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No differences in infection-related mortality ↑ alveolar macrophage HLA-DR expression and lower rates of ventilator pneumonia in treated group by AACN on August 27, 2017 http://ajcc.aacnjournals.org/ Downloaded from lower rate of infection-related mortality. 51 In a similar study of 216 critically ill adult burn patients, IFN-γ administration was associated with no difference in outcomes. 52 To date, no large RCTs using IFN-γ in critical illness have been performed in sepsis.
Adaptive Immune Stimulating Agents
Interleukin-7. IL-7 is a lymphocyte-stimulating cytokine required for T-cell development and for maintenance and restoration of mature T cells. Recombinant human IL-7 (rhIL-7) therapy has been evaluated in preclinical sepsis models, and data suggest benefi cial effects, including increased cytokine production capacity, T-cell proliferation, prevention of lymphocyte apoptosis, and improved survival. [65] [66] [67] [68] [69] [70] Ex vivo treatment of lymphocytes from patients with sepsis with IL-7 signifi cantly improved T-cell proliferation, up-regulation of anti-apoptotic proteins, and IFN-γ production capacity. 63 Whereas rhIL-7 is currently being evaluated in patients with chronic viral infection and cancer, to date it remains unstudied in vivo in the setting of critical illness.
PD-1 and CTLA-4 Blocking Antibodies. In addition to immunostimulatory cytokine therapy, an alternative approach to restore adaptive immune function involves blocking inhibitory molecules such as PD-1 or cytotoxic T-lymphocyte-associated protein (CTLA)-4. Preclinical studies have shown improved lymphocyte survival, cytokine production capacity and improved survival in murine models of bacterial and fungal sepsis that eliminate or block PD-1 or CTLA-4. 
Future Directions in Diagnosis and Treatment of Critical Illness-Induced Immune Suppression
Given the heterogeneity of conditions and the complexity of the immunologic response to critical illness, each patient will be different in presenting characteristics and response to treatment. It is therefore likely that different approaches will be necessary, with the same patient potentially requiring different treatments at various points in time.
It is similarly likely that multiple diagnostic approaches will need to be employed in the ICU. Such an immune monitoring regimen could include an initial risk assessment with genetic and epigenetic determinants, once identifi ed, being evaluated upon admission (Figure 2 ). Serial measurement of innate and adaptive immune function using a combination of cell surface marker analysis and stimulation studies could inform the use and timing of immunostimulatory agents. Patients with clearly identifi ed innate and/or adaptive immune dysfunction would then be appropriately stratifi ed into treatment groups based on their individual immunological defi cits. Furthermore, the patient's individual response to treatment would be longitudinally monitored and adjustments to immunomodulatory therapies made accordingly. Throughout, attention would be paid to avoid immunosuppressive therapies in at-risk patients in favor of an immune-friendly treatment plan. This comprehensive and highly dynamic A future paradigm for the diagnosis and management of critical illness-induced immune suppression. After the onset of critical illness, patients would undergo a risk assessment including genetic and epigenetic screening, followed by prospective, comprehensive immune function monitoring. Should immune suppression be detected, the patient would receive immunostimulatory therapy specifi cally tailored to treat the detected defi cit. Immune-friendly supportive care would be provided throughout.
